APOBEC3A has potent deamination activity in breast cancer cell lines and is strongly associated with mutational burden in breast tumors, suggesting that APOBEC3A is a significant driver of genomic mutations in cancer of distinct histotypes 21. This evidence concerns the gene APOBEC3A and breast carcinoma.